Current and future state of CAR T in Europe

Clinical practices and latest developments with CAR T in lymphoma, gaining a better understanding of challenges facing the real-world adoption of this novel treatment across Europe

Faculty Chair

Catherine Thieblemont, MD, PhD

Hôpital Saint-Louis, Paris, France


Chadi Nabhan, MD, MBA, FACP

Aptitude Health

Look Inside This Report

Download a sample of this report and start discovering the insights

Topics Covered in the Report


  • Update on CAR T: Highlights From EHA and ICML
  • What Differentiates Various CAR T-Cellular Products?
  • Differences and Similarities Between the 2 Approved CAR T-Cellular Products in the Real World
  • The Patient Journeys in the US and France, and discussion on The Patient Journey in Europe
  • CAR T Experience in the US – How Will It Translate in the EU?
  • Sharing Experiences: Real-World CAR T Adoption and Reimbursement in the US
  • Sharing Experiences: Commercial Challenges and Learnings From the US Market
  • Challenges in Administration and Reimbursement in the EU
  • Future of CAR T in the EU
  • New Developments in CAR T
  • Point-of-Care CAR T Therapy in the EU



Paolo Corradini, MD

Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy

Julio Delgado, MD, PhD

Hospital Clínic de Barcelona, Spain

Marie José Kersten, MD, PhD

Academic Medical Center, Amsterdam, The Netherlands

Kim Linton, MBChB, PhD

University of Manchester, United Kingdom

Tom van Meerten, MD, PhD

University Medical Center Groningen, The Netherlands

Sattva Neelapu, MD

MD Anderson Cancer Center, Houston, TX, United States

Max Topp, MD

University of Würzburg, Germany

Explore Available and Upcoming Insight Reports

View Reports